---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-019262"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2026-06-03T11:34:29+00:00"
generated_at: "2026-06-03T11:35:08.369688+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics reports positive Phase 1 data for subcutaneous BRIUMVI; bioavailability >60% vs IV

## Summary
- Mean bioavailability >60% relative to IV; lower bound of 95% CI >55%.
- PK modeling predicts non-inferior total drug exposure for quarterly SC dosing (GMR 1.21, lower 90% CI 1.15).
- Subcutaneous BRIUMVI well tolerated; injection-site reactions <5%, no new safety signals.
- B-cell depletion with SC consistent with IV; supports biologic activity.
- Phase 3 fully enrolled; top-line data expected late 2026 or early 2027; potential approval in 2028.

## SEC filing metadata
- accession: 0001437749-26-019262
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2026-06-03T11:34:29+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/0001437749-26-019262-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774926019262/tgtx20260602_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-019262
- JSON: https://secwatch.observer/filing/0001437749-26-019262.json
- Plain text: https://secwatch.observer/filing/0001437749-26-019262.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.